Market Overview:
The global soft tissue repair market size reached US$ 14.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 19.7 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023 |
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023 |
US$ 14.0 Billion |
Market Forecast in 2032 |
US$ 19.7 Billion |
Market Growth Rate (2024-2032) |
3.8% |
Soft tissues comprise muscles, tendons, fascia, nerves, fat, ligaments, blood vessels, and synovial membranes that connect, surround, and support other structures and organs of the body. Many physical activities can lead to their damage, which further results in pain, sprains, strains, swelling, bursitis, tendinitis, and contusions. As a result, various remedial interventions are utilized for restoring, repairing, and regenerating soft tissues. For instance, scaffolds made using natural polymers like chitosan, gelatin, and alginate are used as biomaterials for their repair. Besides this, the use of allografts and xenografts is also gaining traction for repairing severe damages around the world.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Soft Tissue Repair Market Trends:
The growing participation of individuals, especially children, in professional sports increases the risk of developing an injury in soft tissues. This, in confluence with the increasing concerns among parents about the physical health of their child, represents one of the primary factors influencing the market growth positively. Its repair helps in faster recovery and improving athletic performance. Apart from this, the growing aging population is catalyzing the demand for biomaterials that have high efficiency and can effectively repair damaged soft tissues in a short time. These biomaterials are also used in a variety of soft tissue procedures, including dural tears, chest wall reconstruction, cardiac and cardiovascular surgery, abdominal wall repair, and pelvic organ prolapse treatment. Furthermore, rising incidences of musculoskeletal disorders is promoting the need for biomedical implants to reorganize the bone and its associated soft tissues. Other factors, such as favorable reimbursement policies, the increasing popularity of medical tourism, and rising investments in research and development (R&D) activities, are anticipated to strengthen the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global soft tissue repair market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end use.
Breakup by Product:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Fixation Products
- Tissue Patch/Match
Breakup by Application:
- Orthopedic Surgery
- Breast Reconstruction
- Hernia Repair
- Skin Repair
- Vaginal Sling Repair
- Cardiovascular Surgery
- Others
Breakup by End Use:
- Hospitals and Clinics
- Research and Academic Institutes
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Arthrex Inc., Becton Dickinson and Company, Baxter International Inc., Cryolife Inc., Integra LifeSciences Corporation, Johnson & Johnson, Medtronic Plc, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation and Terumo Corporation.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Product, Application, End Use, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
AbbVie Inc., Arthrex Inc., Becton Dickinson and Company, Baxter International Inc., Cryolife Inc., Integra LifeSciences Corporation, Johnson & Johnson, Medtronic Plc, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation and Terumo Corporation |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |